Beijing Genesky Biotechnologies and Thermo Fisher Scientific Forge Strategic Partnership to Co-Establish a Joint Innovation Laboratory

VCBeat’s New Medicine Channel has learned that Beijing Genetron Health Co., Ltd. (hereinafter referred to as “Genetron Health”) and Thermo Fisher Scientific (hereinafter referred to as “Thermo Fisher”) signed a strategic cooperation agreement at Genetron Health’s Beijing headquarters to jointly establish an Innovation Laboratory. Mr. Chen Chuguang, Chairman of Genetron Health; Ms. Liu Yuying, Technical Director of the project; Mr. Peter Waterman, Vice President of Commercial Operations for Gene and Next-Generation Sequencing Business at Thermo Fisher China; and Mr. Xu Xingguo, Senior Sales Director for Greater China in the Gene Science and Clinical Sequencing Business, among other relevant parties, attended the signing ceremony.

It is understood that Thermo Fisher Scientific will establish a joint innovation laboratory with WeGene, leveraging its capillary electrophoresis technology for applications in precision medicine. Thermo Fisher will provide WeGene with a one-stop testing platform solution encompassing technologies, products, and equipment, while jointly advancing initiatives in scientific research, clinical validation, academic promotion, and technical training. With the rapid development of the precision medicine sector, continuous updates to national policies, and the swift advancement of precise diagnostic and therapeutic technologies, the strategic partnership between WeGene and Thermo Fisher represents a powerful alliance between two industry leaders.

Mr. Chen Chuguang, Chairman of Yuewei Gene

Mr. Chen Chuguang, Chairman of WeGene, stated that since its establishment in 2009, the company has been continuously focused on the research, development, and production of genetic testing technologies and products. WeGene’s products and testing services primarily concentrate on pharmacogenomic testing, genetic disease screening, and personalized diagnosis and treatment of tumors. The company currently serves over 300 hospital clients and is experiencing rapid growth, adding more than 100 served hospitals annually. In 2018, WeGene processed over one million samples through its test kits and third-party testing services, with an annual reagent production capacity reaching five million tests.

Yuewei Genomics holds dozens of invention patents. Despite the abundance of homogeneous products in the market, Yuewei Genomics maintains unique advantages by leveraging its technological strengths to provide users with more accurate, rapid, convenient, and cost-effective products and services tailored to their needs. Given the uneven quality of medical care across China, Yuewei Genomics aims to enhance the timeliness and ease of use of genetic testing while delivering high-quality products at lower prices to its customers.

Through this in-depth collaboration with Thermo Fisher Scientific, WeGene will jointly develop solutions for the capillary electrophoresis platform, facilitating the optimization and iterative improvement of diagnostic products related to genetic diseases, reproductive health, oncology, infectious diseases, and pharmacogenomics in China. This partnership aims to deepen service capabilities and enhance user experience, thereby better meeting market demands.

Mr. Xu Xingguo, Senior Sales Director for Greater China, Gene Sciences and Clinical Sequencing Business, Thermo Fisher Scientific

"As a world leader in scientific services, Thermo Fisher Scientific is dedicated to advancing science to help customers make the world healthier, cleaner and safer. 'Thermo Fisher is pleased to collaborate with outstanding enterprises like WeGene to jointly develop new products and services, achieving mutual benefits while being rooted in China and serving China,' said Xu Xingguo."

Beijing Genetron Health Technology Co., Ltd. focuses on innovative technologies in genetic testing and has developed a series of accurate, rapid, simple, and cost-effective genetic testing kits and reagents.

Headquartered in Beijing, the company operates two Class 10,000 GMP-compliant production facilities in Suzhou High-Tech Zone and Changping District, Beijing, as well as an independent third-party clinical laboratory in Guangzhou. Yuewei Genomics is renowned for its exceptional R&D capabilities and manufacturing capacity. In 2018, Yuewei Genomics conducted over one million genetic tests, surpassing most competitors in the field.

Yuewei Genomics has secured more than 30 patents and achieved world-leading advancements in rapid genetic testing. After years of dedicated effort, Yuewei Genomics has become a highly renowned company within the genetic testing industry. The company’s independently developed products are designed for diverse applications, including forensic DNA identification, reproductive genetics, and pharmacogenomic guidance for cancer, cardiovascular diseases, and mental disorders. Several of these products have even filled gaps in their respective fields.

Thermo Fisher Scientific’s products and services help customers accelerate research in the life sciences and address complex challenges in the analytical field. The company is also committed to advancing medical diagnostics, accelerating drug time-to-market, and enhancing laboratory productivity.

By leveraging its premier brands—Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services—Thermo Fisher Scientific combines innovative technologies, streamlined procurement solutions, and comprehensive services to deliver value to customers.

Thermo Fisher Scientific has been developing in China for 35 years, committed to bringing world-class cutting-edge technologies and products to domestic customers. Helping customers make the world healthier, cleaner, and safer is Thermo Fisher Scientific’s mission.